Graphite Bio is a clinical-stage, next-generation gene editing company driven to discover and develop cures for a wide range of serious and life-threatening diseases. The company is pioneering a precision gene editing approach that has the potential to transform human health by achieving one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s UltraHDR™ gene editing platform takes CRISPR beyond cutting and harnesses the power of high-efficiency precision DNA repair, also known as homology-directed repair (HDR), to precisely correct genetic mutations, replace entire disease-causing genes with functional genes or insert new genes into predetermined, safe locations. Additionally, the company is advancing the development of novel conditioning regimens to help bring curative therapies to more patients. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.

See our Community Guidelines at bit.ly/3c5Pztz. 

Graphite Bio

Beam is a biotechnology company focused on developing gene-based medicines for the treatment of serious genetic disorders.

Beam

bluebird is a clinical-stage gene therapy company that develops gene-based treatments for severe genetic diseases and cancer.

bluebird

CRISPR is a biotechnology company specializing in developing gene-editing technologies for various applications, including treating genetic disorders.

CRISPR

Abmart Inc is a biotechnology company focused on gene editing and genetic therapies for severe diseases.

Abmart Inc

Synthego Corp is a company specializing in gene editing technologies and genetic payload delivery for therapeutic applications.

Synthego Corp

Graphite Bio, Inc. is a biotechnology company focused on developing innovative gene editing therapies to address genetic diseases.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Graphite Bio, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 7, 2024 7:22 PM	863c167a
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 7, 2024 7:22 PM	75376e53
company summary	general
signals	general	Mar 7, 2024 7:22 PM	8acf8c9f
crunchbase trigger	general
crunchbase profile	general
li profile	general	Mar 7, 2024 7:22 PM	1be2ab4b
translate crunchbase fundingrounds	general
peers	general	Mar 7, 2024 7:22 PM	42fd49ed
news basic	general	Mar 7, 2024 7:22 PM	d8d7c6ce
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:GRAPHITEBIO

Graphite Bio, Inc.

Last Close

3.27

21/03 20:00

Market Cap

185.19M

Beta: -

Volume Today

299.41K

Avg: -